Merck + Co., Inc.

Other

Merck Sharp + Dohme Corp.

James B Doherty

Paul E Finke

Shrenik K Shah

William K Hagmann

Conrad P Dorn

Morris Zimmerman

Swaminathan R Natarajan

Robert M Tynebor

Bonnie M Ashe

Meng-Hsin Chen

Luping Liu

Malcolm MacCoss

Kevan R Thompson

Philippe L Durette

Raymond A Firestone

Soumya P Sahoo

Sander G Mills

Dong-Ming Shen

Tsung-Ying Shen

Jeffrey John Hale

Thomas J Lanza, Jr

John E Stelmach

Meng Hsin Chen

Debra L Allison

David A Claremon

Nigel J Liverton

Tesfaye Biftu

Bruce E Witzel

Kathleen M Rupprecht

Peter J Sinclair

Jianming Bao

Steven L Colletti

Michael N Chang

XiaoXia Qian

Richard Berger

Shouwu Miao

Dennis M Schmatz

Charles J McIntyre

Gui-Bai Liang

Julianne A Hunt

Joung L Goulet

Zhen Li

Florida Kallashi

Richard Beresis

Xingfang Hong

Richard T Dean

David D Wisnoski

Scott A Polo

Dennis D Feng

Ernest W Kovacs

Rowena D Ruzck

Bunnie M Ashe

Amy L Kissinger

Shrenik S Shah

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. 

P38 kinase inhibiting agents

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Ophthalmic compositions for treating ocular hypertension

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents Caryl or Cheterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from R; Z represents (CH)PO(OR)(OR*). 

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation 

(Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents

Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis 

(Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described, wherein n is

Substituted azetidinones as anti-inflammatory and antidegenerative agents

Substituted azetidinones are herein disclosed for use in the treatment of various elastase-mediated diseases.

Substituted azetidiones as anti-inflammatory and antidegenerative agents

New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R.sub.4 is (a) ##STR2## or (b) ##STR3## where R.sub.x is carboxy C.sub.1-6 alkyl, benzyloxycarbonylC.sub.1-3 alkyl, or t-butoxycarbonylC.sub.1-3 alkyl, wherein

Growing community of inventors

Montvale, NJ, United States of America

James B Doherty